[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 42 of about 42
1. Pathak KA, Juvekar AS, Radhakrishnan DK, Deshpande MS, Pai VR, Chaturvedi P, Pai PS, Chaukar DA, D'Cruz AK, Parikh PM: In vitro chemosensitivity profile of oral squamous cell cancer and its correlation with clinical response to chemotherapy. Indian J Cancer; 2007 Oct-Dec;44(4):142-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro chemosensitivity profile of oral squamous cell cancer and its correlation with clinical response to chemotherapy.
  • Currently, it is difficult to predict whether a tumor will respond to chemotherapy and which drug(s) will achieve the maximum clinical response.
  • AIMS: To study in vitro chemosensitivity profile of oral cancers and to correlate the in vitro chemosensitivity of oral cancer to clinical response to chemotherapy.
  • SETTINGS AND DESIGN: Prospective study in a tertiary cancer care center.
  • METHODS AND MATERIAL: We prospectively studied the chemosensitivity profile of 57 untreated, advanced, unresectable oral cancers to cisplatin, methotrexate, 5-fluorouracil and their combinations by using histoculture drug response assay (HDRA) and correlated them to the clinical response to chemotherapy.
  • Of these 52 evaluable patients, 47 had primary gingivo-buccal cancers and five had tongue / floor of mouth cancers.
  • Of these, 31 patients with good performance status received two cycles of chemotherapy using one or more of these test drugs.
  • CONCLUSIONS: We found HDRA to be a fairly good predictor of chemo-response of oral cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / pharmacology. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Biological Assay. Cisplatin / pharmacology. Cisplatin / therapeutic use. Female. Fluorouracil / pharmacology. Fluorouracil / therapeutic use. Humans. In Vitro Techniques. Male. Methotrexate / pharmacology. Methotrexate / therapeutic use. Middle Aged. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18322356.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


2. Bidault F, Faivre S, Kuoch V, Petrow P, Temam S, De Baere T, Janot F, Casiraghi O, Luboinski B, Roche A, Sigal R: Hyperselective intra-arterial preoperative chemotherapy in patients with squamous cell carcinoma of the oral cavity: preliminary results. J Neuroradiol; 2006 Oct;33(4):255-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperselective intra-arterial preoperative chemotherapy in patients with squamous cell carcinoma of the oral cavity: preliminary results.
  • OBJECTIVES: To investigate radiological response and findings after Intra Arterial Chemotherapy (IAC) for patients with Squamous Cell Carcinoma (SCC) of the oral cavity.
  • Primary tumors were floor of the mouth (4 patients) and oral tongue (2 patients).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / drug therapy. Cisplatin / administration & dosage. Mouth Neoplasms / diagnosis. Mouth Neoplasms / drug therapy. Taxoids / administration & dosage
  • [MeSH-minor] Female. Humans. Infusions, Intra-Arterial. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome


3. Ogiuchi Y, Maruoka Y, Ando T, Kobayashi M, Ogiuchi H: Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma. Acta Histochem Cytochem; 2008 Jun 27;41(3):39-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma.
  • We conducted a clinicopathologic study on protein and mRNA levels of thymidylate synthase (TS), thymidine phosphorylase (TP) and orotate phosphoribosyl transferase (OPRT) using biopsy tissue specimens before treatment.
  • We studied the mRNA and protein expression as effect predictive factors in chemotherapy.
  • The subjects consisted of 20 cases of untreated oral squamous cell carcinoma who had undergone chemotherapy with TS-1 (16 males and 4 females, tongue in 8 cases, upper gingiva in 3 cases, lower gingiva in 3 cases, buccal mucosa in 5 cases and floor of the mouth in 1 case).
  • Furthermore, regarding males who were less than 70 years of age, stage I and II, well differentiated type and tongue, TS mRNA expression of the responders were lower than that for the nonresponders.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1486-92 [14562021.001]
  • [Cites] Oncol Rep. 2006 Jun;15(6):1417-23 [16685374.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Dec;94(6):717-23 [12464897.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):42-9 [10618604.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2371-6 [9796967.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3223-9 [9336359.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Acta Otolaryngol. 2006 Dec;126(12):1295-302 [17101591.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Mar;35(3):265-9 [16257511.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):884-9 [16189518.001]
  • [Cites] Oral Oncol. 2005 Mar;41(3):276-82 [15743690.001]
  • [Cites] J Am Coll Surg. 2005 Mar;200(3):336-44 [15737843.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1245-50 [15354215.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4116-24 [14519634.001]
  • [Cites] Oral Oncol. 2006 Oct;42(9):880-7 [16757204.001]
  • [Cites] Int J Cancer. 2004 Dec 20;112(6):967-73 [15316940.001]
  • (PMID = 18636111.001).
  • [ISSN] 0044-5991
  • [Journal-full-title] Acta histochemica et cytochemica
  • [ISO-abbreviation] Acta Histochem Cytochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2447914
  • [Keywords] NOTNLM ; oral cancer / orotate phosphoribosyl transferase / thymidine phosphorylase / thymidylate synthase
  •  go-up   go-down


Advertisement
4. Wolter KG, Wang SJ, Henson BS, Wang S, Griffith KA, Kumar B, Chen J, Carey TE, Bradford CR, D'Silva NJ: (-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia; 2006 Mar;8(3):163-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo.
  • Resistance to chemotherapy is a common problem encountered in the treatment of head and neck squamous cell carcinoma (HNSCC).
  • In this study, we assessed the in vivo efficacy of (-)-gossypol in an orthotopic xenograft model of HNSCC, using two human HNSCC cell lines with high Bcl-x(L) expression levels.
  • Both produced tumors in a murine floor-of-mouth model that mimics human HNSCC, exhibiting growth and invasion into adjacent tissues.
  • Mice were randomized into three groups: vehicle control and two daily intraperitoneal (-)-gossypol treatment groups (5 and 15 mg/kg).
  • In the control group, tumors grew progressively, whereas in (-)-gossypol treatment groups, tumor growth was significantly suppressed.
  • Residual tumors remained growth-suppressed for 2 weeks after cessation of (-)-gossypol treatment.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Gossypol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7124-9 [10860979.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):876-85 [16239906.001]
  • [Cites] Nat Cell Biol. 2001 Feb;3(2):183-91 [11175751.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6627-31 [11426648.001]
  • [Cites] Breast Cancer Res Treat. 2001 Apr;66(3):239-48 [11510695.001]
  • [Cites] Laryngoscope. 2002 Apr;112(4):638-44 [12150516.001]
  • [Cites] Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):193-213 [12162702.001]
  • [Cites] J Am Chem Soc. 2002 Oct 9;124(40):11838-9 [12358513.001]
  • [Cites] Int J Cancer. 2003 Aug 20;106(2):160-6 [12800189.001]
  • [Cites] Biochem Pharmacol. 2003 Jul 1;66(1):93-103 [12818369.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2856-65 [12855666.001]
  • [Cites] J Cell Physiol. 2003 Sep;196(3):532-40 [12891710.001]
  • [Cites] J Med Chem. 2003 Sep 25;46(20):4259-64 [13678404.001]
  • [Cites] Oncogene. 2003 Sep 18;22(40):6243-56 [13679863.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jan;130(1):8-14 [14605879.001]
  • [Cites] Chem Biol. 2004 Mar;11(3):389-95 [15123268.001]
  • [Cites] Arch Biochem Biophys. 2004 Aug 15;428(2):179-87 [15246875.001]
  • [Cites] Int J Oncol. 2004 Aug;25(2):445-51 [15254743.001]
  • [Cites] J Pathol. 2004 Aug;203(4):927-32 [15258995.001]
  • [Cites] Cancer Cells. 1990 Aug-Sep;2(8-9):275-80 [2223389.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Cancer Metastasis Rev. 1992 Sep;11(2):121-39 [1327566.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1707-14 [7511048.001]
  • [Cites] J Neurooncol. 1994;19(1):25-35 [7815102.001]
  • [Cites] Behring Inst Mitt. 1996 Oct;(97):72-100 [8950468.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Jun;55(6):613-23; discussion 623-5 [9191644.001]
  • [Cites] Br J Cancer. 1997;76(1):21-8 [9218727.001]
  • [Cites] Melanoma Res. 1997 Oct;7(5):364-72 [9429219.001]
  • [Cites] Gynecol Oncol. 1998 Sep;70(3):398-403 [9790794.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2039-46 [9815595.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7757-63 [15570010.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):13-21 [15657349.001]
  • [Cites] Int J Cancer. 2005 Mar 10;114(1):32-8 [15523684.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Mol Cancer Ther. 2005 Jul;4(7):1096-104 [16020667.001]
  • [Cites] Life Sci. 2000 Oct 20;67(22):2663-71 [11105982.001]
  • (PMID = 16611409.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA97248; United States / NCI NIH HHS / CA / P50 CA097248; United States / NIDCR NIH HHS / DE / R01 DE013346; United States / NCI NIH HHS / CA / R01 CA083087; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / R01 CA83087; United States / NIDCD NIH HHS / DC / T32 DC05356; United States / NIDCR NIH HHS / DE / K08 DE014620; United States / NIDCR NIH HHS / DE / DE00452-01; United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NIDCD NIH HHS / DC / P30 DC005188; United States / NIDCR NIH HHS / DE / K23 DE000452; United States / NIDCR NIH HHS / DE / DE014620-01A1; United States / NIDCD NIH HHS / DC / T32 DC005356; United States / NIDCD NIH HHS / DC / P30 DC05188; United States / NIDCR NIH HHS / DE / R01 DE13346
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / BCL2L1 protein, human; 0 / Neoplasm Proteins; 0 / bcl-X Protein; KAV15B369O / Gossypol
  • [Other-IDs] NLM/ PMC1578526
  •  go-up   go-down


5. Kruser TJ, Armstrong EA, Ghia AJ, Huang S, Wheeler DL, Radinsky R, Freeman DJ, Harari PM: Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer. Int J Radiat Oncol Biol Phys; 2008 Oct 1;72(2):534-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer.
  • PURPOSE: To examine the interaction between panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, and radiation in head-and-neck squamous cell carcinoma and non-small-cell lung cancer cell lines and xenografts.
  • METHODS AND MATERIALS: The head-and-neck squamous cell carcinoma lines UM-SCC1 and SCC-1483, as well as the non-small-cell lung cancer line H226, were studied.
  • In vitro assays were performed to assess the effect of panitumumab on radiation-induced cell signaling, apoptosis, and DNA damage.
  • Panitumumab augmented radiation-induced DNA damage by 1.2-1.6-fold in each of the cell lines studied as assessed by residual gamma-H(2)AX foci after radiation.
  • In vivo, the combination therapy of panitumumab and radiation was superior to panitumumab or radiation alone in the H226 xenografts (p = 0.01) and showed a similar trend in the SCC-1483 xenografts (p = 0.08).
  • These data suggest that clinical investigations examining the combination of radiation and panitumumab in the treatment of epithelial tumors warrant additional pursuit.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2005 Feb;74(2):109-15 [15734198.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805 [15701870.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):31182-9 [16000298.001]
  • [Cites] Radiother Oncol. 2005 Aug;76(2):157-61 [16024112.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1072-8 [16505426.001]
  • [Cites] Clin Lung Cancer. 2006 Jan;7(4):285-7 [16512986.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3162-8 [16540667.001]
  • [Cites] Cell Signal. 2006 Oct;18(10):1537-48 [16713182.001]
  • [Cites] Mol Biol Cell. 2002 Jul;13(7):2233-44 [12134064.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4300-6 [12154033.001]
  • [Cites] Oncogene. 2002 Oct 31;21(50):7611-8 [12400004.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1535-42 [12393476.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5057-62 [12679524.001]
  • [Cites] Int J Radiat Biol. 2003 Jul;79(7):581-5 [14530167.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90 [14967460.001]
  • [Cites] Radiat Res. 1993 Oct;136(1):65-70 [8210340.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):813-9 [8040028.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):91-8 [8083133.001]
  • [Cites] Radiat Res. 1996 Jan;145(1):81-5 [8532841.001]
  • [Cites] Oncogene. 1997 Sep 4;15(10):1191-7 [9294612.001]
  • [Cites] Radiat Oncol Investig. 1997;5(4):180-6 [9327497.001]
  • [Cites] Biochim Biophys Acta. 1997 Oct 11;1358(3):289-99 [9366260.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):257-65 [10037173.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):781-7 [17096332.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1552-61 [17332301.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3712-8 [17704420.001]
  • [Cites] Nat Biotechnol. 2007 Oct;25(10):1134-43 [17921999.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1935-40 [10213503.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2884-90 [10537357.001]
  • [Cites] Radiother Oncol. 1999 Aug;52(2):137-48 [10577699.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):701-8 [10690556.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4227-32 [10760290.001]
  • [Cites] Cancer Biother Radiopharm. 1999 Dec;14(6):451-63 [10850332.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2489-95 [10851047.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2166-74 [10873065.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4343-50 [11106252.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):474-7 [11567823.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):42462-7 [11571274.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1236-43 [10096554.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3328-35 [15833866.001]
  • (PMID = 18793955.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009614-18; United States / NCI NIH HHS / CA / T32 CA009614-14; United States / NCI NIH HHS / CA / T32 CA009614-11; United States / NCI NIH HHS / CA / T32 CA009614-10; United States / NCI NIH HHS / CA / CA009614-15; United States / NCI NIH HHS / CA / T32 CA009614-15; United States / NCI NIH HHS / CA / CA009614-16A1; United States / NCI NIH HHS / CA / T32 CA009614-16A1; United States / NCI NIH HHS / CA / R01 CA113448-02; United States / NCI NIH HHS / CA / CA113448-04; United States / NCI NIH HHS / CA / R01 CA113448; United States / NCI NIH HHS / CA / CA009614-14; United States / NCI NIH HHS / CA / CA113448-01A1; United States / NCI NIH HHS / CA / R01 CA113448-03; United States / NCI NIH HHS / CA / CA009614-12; United States / NCI NIH HHS / CA / CA009614-17; United States / NCI NIH HHS / CA / T32 CA009614; United States / NCI NIH HHS / CA / R01 CA113448-05; United States / NCI NIH HHS / CA / CA009614-11; United States / NCI NIH HHS / CA / R01 CA 113448-01; United States / NCI NIH HHS / CA / T32 CA009614-13; United States / NCI NIH HHS / CA / CA009614-18; United States / NCI NIH HHS / CA / CA009614-13; United States / NCI NIH HHS / CA / T32 CA009614-17; United States / NCI NIH HHS / CA / T32 CA009614-12; United States / NCI NIH HHS / CA / R01 CA113448-04; United States / NCI NIH HHS / CA / CA009614-10; United States / NCI NIH HHS / CA / R01 CA113448-01A1; United States / NCI NIH HHS / CA / CA113448-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Proliferating Cell Nuclear Antigen; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / panitumumab; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ NIHMS220555; NLM/ PMC2927815
  •  go-up   go-down


6. Epperly MW, Franicola D, Zhang X, Nie S, Greenberger JS: Effect of EGFR antagonists gefitinib (Iressa) and C225 (Cetuximab) on MnSOD-plasmid liposome transgene radiosensitization of a murine squamous cell carcinoma cell line. In Vivo; 2006 Nov-Dec;20(6B):791-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of EGFR antagonists gefitinib (Iressa) and C225 (Cetuximab) on MnSOD-plasmid liposome transgene radiosensitization of a murine squamous cell carcinoma cell line.
  • Radiation therapy of tumors of the head and neck region is compromised by dose limiting toxicity of normal tissues including the oral cavity and oropharyngeal mucosa.
  • MnSOD-Plasmid Liposome (MnSOD-PL) intraoral gene therapy has been demonstrated to decrease normal tissue toxicity and also improve survival in mice with orthotopic SCC-VII squamous cell tumors on the floor of the mouth.
  • Furthermore, intravenous administration of MnSOD-PL in mice with orthotopic tumors, or addition of MnSOD-PL to tumor cell lines in vitro produces a radiosensitizing effect attributable to differences in antioxidant pool responses of tumor cells compared to normal tissues following irradiation.
  • To determine whether EGF receptor (EGFR) antagonists Iressa, or Cetuximab provided further improvement of radiation killing of squamous cell tumors, MnSOD-PL transfected or control SCCVII tumor cells were irradiated in vitro, and then the effect of EGFR receptor antagonists was tested.
  • Cells transfected with MnSOD-PL were relatively radiosensitive D0 = 1.244 +/- 0.126 Gy compared to control D0 = 3.246 +/- 0.087 (p < 0.0001).
  • Clonogenic radiation survival curves of SCCVII cells demonstrated radiosensitization by Iressa D0 = 2.770 +/- 0.134 Gy (p = 0.0264), but no significant radiosensitizing effect of Cetuximab D0 = 3.193 +/- 0.309 (p = 0.7338).
  • The combination of MnSOD-PL plus Iressa further increased radiosensitivity of SCC-VII cells in vitro D0 = 0.785 +/- 0.01064 (p < 0.0001).
  • The results suggest some synergy of the effectiveness of the EGFR antagonist Iressa on increasing the radiation killing of SCC-VII cells that supplements MnSOD-PL tumor radiosensitization.
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / pharmacology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / genetics. Cell Survival / radiation effects. Cetuximab. Dose-Response Relationship, Radiation. Liposomes. Mice. Transfection. Transgenes / genetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] In Vivo. 2007 Nov-Dec;21(6):1172
  • (PMID = 17203769.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Liposomes; 0 / Quinazolines; EC 1.15.1.1 / Superoxide Dismutase; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab; S65743JHBS / gefitinib
  •  go-up   go-down


7. Kuruvila S, Dalal M, Sivanesan B: Bullous variant of acral erythema due to methotrexate. Indian J Dermatol Venereol Leprol; 2006 Nov-Dec;72(6):440-2
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chemotherapy-induced acral erythema is a painful erythema of the palms and soles which occurs following chemotherapy.
  • We present a 40-year-old male patient, a biopsy proven case of squamous cell carcinoma of the floor of the mouth, who developed a bullous variant of acral erythema after a single intravenous dose of methotrexate.
  • [MeSH-minor] Adult. Carcinoma, Squamous Cell / drug therapy. Drug Eruptions / pathology. Humans. Injections, Intravenous. Male. Mouth Neoplasms / drug therapy. Stomatitis / chemically induced. Stomatitis / pathology

  • MedlinePlus Health Information. consumer health - Foot Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179620.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


8. Kawashiri S, Kojima K, Kumagai S, Nakagawa K, Yamamoto E: Effects of chemotherapy on invasion and metastasis of oral cavity cancer in mice. Head Neck; 2001 Sep;23(9):764-71
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of chemotherapy on invasion and metastasis of oral cavity cancer in mice.
  • BACKGROUND: Using an orthotopic implantation model in which oral cancer invasion and metastasis can be reproduced, we investigated the inhibitory effects of anticancer agents on invasion and metastasis.
  • METHODS: A highly invasive and metastatic human oral squamous cell carcinoma cell line, OSC-19, was implanted into the oral floor of nude mice, and cisplatin or peplomycin was administered to the mice 7 or 14 days after implantation.
  • The effects of each anticancer drug and different administration timings on cancer invasion and metastasis were investigated.
  • RESULTS: Tumor size and the ratio of proliferating cell nuclear antigen-positive cells was significantly reduced.
  • In the control group, the tumors showed grade 4C mode of invasion, whereas in the groups treated with anticancer drugs, grade 3 was observed in 77.3% of the mice, with an inhibitory effect on tumor invasion being observed.
  • CONCLUSIONS: Chemotherapy is effective not only for tumor diminution but also for inhibiting invasion and metastasis.
  • In light of these effects, administration of anticancer drugs may be clinically useful in this regard.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cell Line. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Disease Models, Animal. Drug Administration Schedule. Lymphatic Metastasis. Mice. Mice, Nude. Neoplasm Invasiveness. Neoplasm Metastasis. Peplomycin / administration & dosage. Peplomycin / therapeutic use

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11505487.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 56H9L80NIZ / Peplomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Shikani AH, Domb AJ: Polymer chemotherapy for head and neck cancer. Laryngoscope; 2000 Jun;110(6):907-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymer chemotherapy for head and neck cancer.
  • OBJECTIVES: To study a new method of delivery of chemotherapy for the treatment of squamous cell carcinomas (SCCs) of the head and neck, to evaluate the pharmacokinetics of four anticancer agents (cisplatin, fluorouracil [5-FU], methotrexate [MTX], and paclitaxel) loaded into the biodegradable polymer, polyanhydride polymer poly(FAD:SA), and to evaluate the effectiveness and toxicity of the drug-polymer combination against human SCCs, both in vitro and in vivo.
  • STUDY DESIGN: Poly(FAD:SA) was loaded with different chemotherapeutic drugs and its in vitro and in vivo drug release and tissue penetration characteristics were studied.
  • The biocompatibility and toxicity of the polymer-drug combination were determined.
  • The effectiveness of the drug-polymer was evaluated against three different human SCCs (larynx O11, pharynx FADU, and floor of mouth UM- SCC1) cultured in vitro and in nude mice carrying human SCC xenografts.
  • METHODS: The in vitro drug release pharmacokinetics of the drugs were performed using atomic absorption spectrometry for cisplatin and high-pressure liquid chromatography for the 5-FU, MTX, and paclitaxel studies.
  • RESULTS: All four chemotherapy drugs demonstrated a continuous release that followed first-order kinetics from the polymer.
  • When a small amount of polymer (1-2 g) was added to the cell culture and left for 7 days, 96.6% of the UM-SCC1 cells, 86.9% of the FADU cells, and 94.6% of the O11 cells were killed.
  • The tumor animal model was the nude mouse carrying human floor of mouth SCC xenografts.
  • Different amounts of cisplatin were incorporated into the polymers (5% and 7% drug/polymer at a weight/weight [wt/wt] load).
  • CONCLUSIONS: The study results indicate that polymer chemotherapy is effective against a variety of SCCs of the head and neck, both in vitro and in vivo, and may become a useful therapeutic option for head and neck cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Polymers
  • [MeSH-minor] Animals. Biodegradation, Environmental. Chromatography, High Pressure Liquid / methods. Cisplatin / administration & dosage. Cisplatin / pharmacokinetics. Disease Models, Animal. Drug Carriers. Humans. Methotrexate / administration & dosage. Methotrexate / pharmacokinetics. Mice. Mice, Nude

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10852503.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Polymers; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


10. Maruoka Y, Ando T, Hoshino M, Ogiuchi Y, Nishihara N, Okamoto T, Fukada K, Kuwazawa T, Ogiuchi H: [Combination chemotherapy with nedaplatin (CDGP) and 5-FU for oral cancer]. Gan To Kagaku Ryoho; 2002 Mar;29(3):421-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination chemotherapy with nedaplatin (CDGP) and 5-FU for oral cancer].
  • Chemotherapy using CDGP plus 5-FU was evaluated in patients with oral cancer.
  • The subjects were patients with squamous cell carcinoma of the oral cavity who had not received any therapy, comprising 7 patients with carcinoma of the tongue, 2 with buccal carcinoma, 2 with maxillary gingival carcinoma, and 1 with carcinoma of the oral floor.
  • This treatment was one course of therapy, and patients received 1 or 2 courses.
  • Toxicities experienced by patients were mild (grade 2 or lower) gastrointestinal disorders (including nausea/vomiting) and renal impairment, while grade 3 leukopenia and thrombocytopenia developed in 1 patient each and grade 4 thrombocytopenia occurred in another patient.
  • Thus, patients receiving CDGP + 5-FU therapy should be closely monitored for hematologic toxicity.
  • Since CDGP + 5-FU therapy achieved a good response rate (75%) in the treatment of squamous cell carcinoma of the oral cavity, we plan to use this therapy in the future and assess its benefit in a larger number of patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leukopenia / chemically induced. Male. Middle Aged. Nausea / chemically induced. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Vomiting, Anticipatory / etiology

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11915732.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Grau JJ, Domingo J, Blanch JL, Verger E, Castro V, Nadal A, Alós L, Estapé J: Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study. Oncology; 2002;63(4):338-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study.
  • OBJECTIVES: To determine outcomes in local-regional control and overall survival in patients with squamous locally advanced cancer of the oral cavity, based on intention-to-treat with neoadjuvant chemotherapy followed by surgery or radiation therapy.
  • All had squamous cell carcinomas of the oral cavity in stage III or in nonmetastatic stage IV and were selected for surgery or radiation therapy (if located in the tonsils or in the base of the tongue).
  • Chemotherapy was based on cisplatin 120 mg/m(2) i.v. day 1 plus bleomycin 20 mg/m(2) days 1-5 in continuous i.v. perfusion or plus 5-fluorouracil 1,000 mg/m(2) days 1-5 in continuous i.v. perfusion.
  • Definitive surgery (n = 73; plus adjuvant radiation therapy) or definitive radiation therapy (n = 131) was performed.
  • RESULTS: One hundred thirty-five out of 204 (66%) patients were chemotherapy responders, 16% complete and 50% partial.
  • One hundred ninety-four patients (95%) completed 2 courses of chemotherapy.
  • After neoadjuvant chemotherapy, 34 out of 46 patients considered inoperable initially (74%) obtained a disease-free status with surgery.
  • Eighty-three percent of surgical patients obtained a disease-free status (initial tumor control) versus 72% of radiation therapy patients.
  • A better prognosis was observed in stage III over IV (p = 0.02); primary tumor in the retromolar trigone, palate or buccal mucosa over tongue, tonsil or floor of the mouth (p = 0.0085); negative cervical nodes over positive (p = 0.0186); responders to chemotherapy over nonresponders (p = 0.0003); and adjuvant postsurgical radiation therapy (p = 0.0013).
  • CONCLUSIONS: In locally advanced squamous cell carcinoma of the oral cavity, neoadjuvant chemotherapy induces a high response rate that may facilitate definitive surgery or radiotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Survival Analysis

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12417788.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Iwasaki A, Tanizaki A, Ohbayashi Y, Miyake M, Nagahata S, Takahashi N: [Chemotherapy with nedaplatin for an oral floor cancer patient undergoing chronic hemodialysis]. Gan To Kagaku Ryoho; 2000 Dec;27(14):2231-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy with nedaplatin for an oral floor cancer patient undergoing chronic hemodialysis].
  • Since pharmacokinetics in patients undergoing hemodialysis differs from that in patients with normal renal function, the administration of chemotherapeutic drugs to a patient with renal failure should be sufficiently considered beforehand to avoid adverse effects.
  • A case of carcinoma of the oral floor in a 69 year-old male receiving ongoing hemodialysis due to chronic renal failure is reported.
  • Chemotherapy was given using nedaplatin and 5-FU; surgery was performed as well.
  • However, the value of the area under the blood concentration time curve (AUC), which is considered a target index of administration, was close to the value in patients with normal renal function.
  • No severe side effects were observed after chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Renal Dialysis
  • [MeSH-minor] Aged. Drug Administration Schedule. Fluorouracil / administration & dosage. Fluorouracil / pharmacokinetics. Humans. Kidney Failure, Chronic / complications. Kidney Failure, Chronic / therapy. Male. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / pharmacokinetics

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11142167.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Yamamoto G, Tanaka A, Tsuda Y, Shimada T, Nishida T, Nishikawa M, Inoda H, Takigami K, Yoshitake K: [A case of large carcinoma of the tongue and mouth floor, in which chemotherapy using a combination of nedaplatin and 5-FU was effective]. Gan To Kagaku Ryoho; 2002 Dec;29(13):2533-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of large carcinoma of the tongue and mouth floor, in which chemotherapy using a combination of nedaplatin and 5-FU was effective].
  • We encountered a case of extensive squamous cell carcinoma ranging from the tongue to the mouth floor, in which chemotherapy using a combination of nedaplatin and 5-FU was effective.
  • The patient was a 46-year-old male, who noticed a small mass in the mouth floor in September 2000, and visited the department of oral and maxillofacial surgery at a hospital on October 12, 2000.
  • A 27 x 15 mm tumor with erosion was noted on the mouth floor, which was diagnosed as squamous cell carcinoma by biopsy, and the patient was referred to our department for treatment on November 16, 2000.
  • MRI detected a tumor of approximately 2 cm in diameter in the area ranging from the median area of the tongue to the right ventral side of the tongue, which protruded on the mouth floor side.
  • Two courses of combination chemotherapy using nedaplatin and 5-FU were performed.
  • Adverse effects of gastralgia and stomatitis occurred, but they gradually disappeared with time.
  • The tumor with erosion in the tongue and mouth floor and induration disappeared 2 weeks after administration.
  • Postoperative MR showed no abnormal signals in T2-weighed images, suggesting that the tumor in the right mouth floor had almost disappeared.
  • External irradiation (40 Gy/20 times/28 days, 2 Gy/day, opposing bilateral portal irradiation) between March 13 and April 9, 2001, and micro-selection high dose fractionated interstitial irradiation (42 Gy/7 times/6 days, 6 Gy/1 time) April 18-23, 2001 were performed as booster therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Neoplasms, Multiple Primary / drug therapy. Tongue Neoplasms / drug therapy
  • [MeSH-minor] Brachytherapy. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12506477.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Németh Z, Szigeti K, Máthé M, Szabó G, Velich N, Suba Z: Effect of induction chemotherapy on changes of laminin and syndecan expression in oral squamous cell carcinomas: a prospective, randomized, clinicopathologic and immunohistochemical study. J Craniofac Surg; 2005 Mar;16(2):205-12
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of induction chemotherapy on changes of laminin and syndecan expression in oral squamous cell carcinomas: a prospective, randomized, clinicopathologic and immunohistochemical study.
  • Sixty patients with tumors of the floor of the mouth or of the tongue (T2N0-1-2M0) were randomized into three treatment groups.
  • The first two groups participated in low-dose inductive chemotherapy, surgery, and then radiotherapy, whereas the third control group underwent only surgery and radiotherapy.
  • In all three groups, studies were made of the stage, grade, sex, localization, extents of expression of the pretreatment laminin and syndecan-1 and the cancer specific survival rate, and the correlations among these.
  • The response to neoadjuvant chemotherapy was assessed by means of a method that we developed, involving measurement of the degree of histologic regression observed in response to chemotherapy.
  • Immunohistochemical methods were applied to investigate the changes in degree of expression of laminin and syndecan-1 in response to the medication and their correlations with the survival.
  • However, there was a significant difference between the survival indices of those who participated in cytostatic treatment (70%) and the control group (40%).
  • Our model measuring the extent of histologic regression clearly demonstrated that the survival indices of the patients who responded to the neoadjuvant cytostatic treatment with adequate tissue regression were better than those of the patients who responded to the treatment to only a decreased extent or not at all.
  • The changes in the expressions of laminin and syndecan-1 in response to cystostatic treatment proved to be important predictive factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Laminin / drug effects. Membrane Glycoproteins / drug effects. Mouth Neoplasms / drug therapy. Proteoglycans / drug effects
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Forecasting. Humans. Immunohistochemistry. Male. Middle Aged. Mouth Floor / drug effects. Mouth Floor / surgery. Neoadjuvant Therapy. Prognosis. Prospective Studies. Radiotherapy, Adjuvant. Remission Induction. Syndecan-1. Syndecans. Tongue Neoplasms / drug therapy. Tongue Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15750416.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Laminin; 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans
  •  go-up   go-down


15. Sung CK, Choi B, Wanna G, Genden EM, Woo SL, Shin EJ: Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma. Laryngoscope; 2008 Feb;118(2):237-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
  • We previously demonstrated recombinant VSV vectors incorporating viral fusion protein (rVSV-F) and interleukin 12 (rVSV-IL12) to have significant antitumor effects against squamous cell carcinoma (SCC) in a murine model.
  • Here we evaluate the potential to combine a potent chemotherapeutic agent for SCC (cisplatin) with rVSV-F and rVSV-IL12 to improve efficacy.
  • STUDY DESIGN: In vitro, three SCC cell lines were tested using rVSV-F and rVSV-IL12 with cisplatin, monitoring viral replication and cell survival.
  • In an orthotopic floor of mouth murine SCC model, intratumoral injections of virus combined with systemic cisplatin were tested for tumor control and animal survival.
  • RESULTS: In vitro, virus and cisplatin combination demonstrated rapid replication and enhanced tumor cell kill.
  • In vivo, combined rVSV-F with cisplatin reduced tumor burden and improved survival (P = .2 for both), while rVSV-IL12 monotherapy had better tumor control (P = .06) and survival (P = .024) than combination therapy.
  • CONCLUSIONS: Addition of cisplatin did not affect the ability of either virus to replicate in or kill murine SCC cells in vitro.
  • In vivo, combination therapy enhancedrVSV-F antitumor activity, but diminished rVSV-IL12 antitumor activity.
  • Combination therapy may provide useful treatment for SCC with the development of more efficient viral vectors in combination with different chemotherapy agents or immunostimulatory agents.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / therapy. Interleukin-12 / genetics. Oncolytic Virotherapy / methods. Vesiculovirus / genetics. Viral Fusion Proteins / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Cisplatin / therapeutic use. Combined Modality Therapy. Disease Models, Animal. Female. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy. Head and Neck Neoplasms / virology. Membrane Glycoproteins. Mice. Mice, Inbred C3H. Mouth Floor / pathology. Mouth Floor / virology. Polymerase Chain Reaction. RNA, Viral / genetics. Recombinant Fusion Proteins. Survival Rate. Viral Envelope Proteins

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043494.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / G protein, vesicular stomatitis virus; 0 / Membrane Glycoproteins; 0 / RNA, Viral; 0 / Recombinant Fusion Proteins; 0 / Viral Envelope Proteins; 0 / Viral Fusion Proteins; 187348-17-0 / Interleukin-12; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Reuther T, Posselt NK, Rabbels J, Kübler AC: [Oral squamous cell carcinoma Retrospective analysis of therapy results and prognosis by neoadjuvant, preoperative radio-chemotherapy]. Mund Kiefer Gesichtschir; 2006 Jan;10(1):18-29
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oral squamous cell carcinoma Retrospective analysis of therapy results and prognosis by neoadjuvant, preoperative radio-chemotherapy].
  • We investigated the charts of 129 patients treated for oral squamous cell carcinoma (SCC) in the Department of Oral and Maxillofacial Surgery, University of Cologne, between 1995 and 2004.
  • Only patients treated preoperatively with combined radio-chemotherapy (carboplatin/39.6 Gy) were included.
  • The purpose of the present study was to show the therapeutic outcome and the survival rates for this regimen.
  • The floor of the mouth was the most common location (48.1%), and three out of four tumours (76.7%) had a G2 grading, while 82.9% were keratinized.
  • Grade T4 was most the common (53.4%), and all patients were operated after preoperative treatment.
  • In 34.1% there were viable tumour cells in the cervical lymph nodes, whereas in 66.7% these cells were found in the primary tumour despite preoperative treatment.
  • A total of 38.8% of patients showed a recurrence of SCC.
  • The overall survival time of the disease was significantly influenced by pT (P=0.004), pN (P>0.001), R0 resections (P=0.0002), viable tumour cells in lymph node metastasis (P=0.0001), viable tumour cells in the primary (P=0.0004) and recurrence of the disease (P>0.001).
  • In comparison to the current literature, no improvements in prognosis and survival of oral squamous cell carcinoma could be observed.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / drug therapy. Mouth Neoplasms / radiotherapy. Neoadjuvant Therapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neck Dissection. Neoplasm Staging. Prognosis. Retrospective Studies. Surgical Flaps. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:91-3 [1639328.001]
  • [Cites] Acta Otolaryngol. 1995 Nov;115(6):833-8 [8749208.001]
  • [Cites] Int J Oral Maxillofac Surg. 1993 Apr;22(2):102-7 [8320445.001]
  • [Cites] Osterr Z Stomatol. 1983 Jun;80(6):216-27 [6583641.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:43-5 [1639309.001]
  • [Cites] Mund Kiefer Gesichtschir. 2002 Mar;6(2):91-7 [12017879.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:69-70 [1322346.001]
  • [Cites] Mund Kiefer Gesichtschir. 1998 Jan;2(1):11-3 [9522566.001]
  • [Cites] Mund Kiefer Gesichtschir. 2000 May;4 Suppl 1:S216-25 [10938662.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:26-9 [1639303.001]
  • [Cites] Strahlenther Onkol. 1989 Sep;165(9):647-51 [2678546.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:5-8 [1639312.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:33-6 [1639306.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 May;118(5):486-7 [1571117.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:108-10 [1639292.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1990;35:60-3 [1695600.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):394-7 [12076706.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:111-5 [1639293.001]
  • [Cites] JAMA. 1987 Dec 11;258(22):3286-93 [3316722.001]
  • [Cites] Plast Reconstr Surg. 1979 Sep;64(3):299-305 [382205.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:21-2 [1639300.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1968;13:30-8 [5276891.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:65-8 [1639318.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1990;35:57-60 [2373435.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:104-8 [1639291.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:13-7 [1639298.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:59-61 [1639316.001]
  • [Cites] HNO. 1993 Aug;41(8):380-4 [8407379.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Feb;52(2):149-54 [8295049.001]
  • [Cites] J Otolaryngol. 1989 Apr;18(3):105-8 [2716083.001]
  • [Cites] Zahn Mund Kieferheilkd Zentralbl. 1986;74(2):161-9 [2939663.001]
  • [Cites] Cancer. 1977 Jan;39(1):204-9 [832234.001]
  • [Cites] Dtsch Z Mund Kiefer Gesichtschir. 1988 Jul-Aug;12(4):293-302 [3240611.001]
  • [Cites] Head Neck Surg. 1986 Sep-Oct;9(1):13-8 [3623928.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:86-8 [1639326.001]
  • [Cites] Dtsch Z Mund Kiefer Gesichtschir. 1984 Jul-Aug;8(4):264-70 [6084570.001]
  • [Cites] Otolaryngol Head Neck Surg. 1998 Feb;118(2):272-5 [9482566.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:37-9 [1639307.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Apr;125(4):379-82 [10208674.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:48-50 [1639311.001]
  • [Cites] Mund Kiefer Gesichtschir. 2000 May;4 Suppl 1:S142-54 [10938654.001]
  • [Cites] J Laryngol Otol. 1966 Aug;80(8):831-8 [5945238.001]
  • [Cites] Dtsch Zahn Mund Kieferheilkd Zentralbl Gesamte. 1973 Feb;60(2):81-93 [4122694.001]
  • [Cites] Cancer. 1994 Jan 1;73(1):187-90 [8275423.001]
  • [Cites] Dtsch Z Mund Kiefer Gesichtschir. 1990 Jul-Aug;14(4):242-9 [2134647.001]
  • [Cites] Plast Reconstr Surg. 1982 Apr;69(4):591-600 [7071197.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:82-6 [1639325.001]
  • [Cites] Cancer Treat Rep. 1985 Sep;69(9):933-9 [3928158.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1994;39:5-12 [8088670.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:30-3 [1639305.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Sep;119(9):958-63 [8357596.001]
  • [Cites] Dtsch Zahnarztl Z. 1951 Nov 1;6(21):1173-80 [14936642.001]
  • [Cites] Int J Oral Maxillofac Surg. 1989 Feb;18(1):39-42 [2497209.001]
  • [Cites] Mund Kiefer Gesichtschir. 2004 Jul;8(4):217-22 [15293116.001]
  • [Cites] Mund Kiefer Gesichtschir. 1998 Mar;2(2):58-61 [9567059.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:46-7 [1639310.001]
  • [Cites] Br J Plast Surg. 1980 Apr;33(2):277-82 [6446341.001]
  • [Cites] Cancer. 1994 Nov 1;74(9 Suppl):2719-25 [7954292.001]
  • [Cites] J Am Dent Assoc. 1976 Mar;92(3):571-4 [1062459.001]
  • (PMID = 16397802.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Yamamoto G, Shimada T, Nishida T, Ishida Y, Iba T, Nakata T, Ohtsuki T, Takigami K, Yamaguchi Y, Yoshitake K, Tanaka A, Tsuda Y: [Evaluation of a combination chemotherapy with nedaplatin and 5-FU for oral cancers]. Gan To Kagaku Ryoho; 2001 Aug;28(8):1111-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of a combination chemotherapy with nedaplatin and 5-FU for oral cancers].
  • Nedaplatin (cis-diammine-glycolato platinum: CDGP) is a platinum compound with a molecular weight of 303.18 that was recently developed in Japan.
  • In this study, we performed combined therapy of CDGP and fluorouracil (5-FU) for 8 patients with oral cancers, and evaluated the results to elucidate the clinical effect and adverse side effects.
  • The subjects were 8 patients with squamous cell carcinoma (5 males and 3 females aged 33-65 years).
  • The primary carcinoma regions were the tongue in 5 patients, oral floor in 2 patients, and mandibular gingiva in 1 patient.
  • The T-classification was T2 in 6 patients and T4 in 2 patients, and the clinical staging was Stage II in 5 patients, Stage III in 1 patient and Stage IV in 2 patients.
  • Although the oral cancers in this study were extroverted superficial ulcerative cancers, and the number of patients was low at 8, this combined therapy is considered useful and worth evaluating in further accumulated cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Remission Induction

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11525027.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Bachmann G, Hess A, Guntinas-Lichius O, Jungehülsing M: [Palliative surgery in squamous cell carcinoma of the anterior floor of the mouth]. HNO; 2004 Jul;52(7):627-30
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Palliative surgery in squamous cell carcinoma of the anterior floor of the mouth].
  • [Transliterated title] Palliative Chirurgie bei Plattenepithelkarzinom des vorderen Mundbodens.
  • A 62 year old patient presented with a bleeding, incurable squamous cell carcinoma of the anterior floor of the mouth.
  • After four palliative surgical procedures, a definitive and a palliative radiation therapy and a palliative chemotherapy, the patient remained free of tumor in the head and neck region for 2 years after the initial treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / secondary. Head and Neck Neoplasms / surgery. Mouth Floor / surgery. Mouth Neoplasms / surgery. Palliative Care
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy, Adjuvant. Surgical Flaps


19. Reuther T, Kübler AC, Staff CJ, Flechtenmacher C, Haase T, Zillmann U: The RAG 2 mouse model for xenografted human oral squamous cell carcinoma. Contemp Top Lab Anim Sci; 2002 Mar;41(2):31-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The RAG 2 mouse model for xenografted human oral squamous cell carcinoma.
  • Animal tumor models are still essential for the development of new medication and therapy concepts.
  • In the field of human oral squamous cell cancer, there are few reliable xenografted tumor models available.
  • Therefore, during a two-course experiment, we established a new xenografted tumor model of human oral squamous cell cancer.
  • The tumor growth rates of two different tumor cell lines were compared in the inbred immunodeficient CD-17-RAG 2 mouse, NMRI-SCID mouse (scid/scid), and Swiss nude mouse (nu/nu).
  • The tumor cell line from a lymphnode metastasis of an oral squamous cell carcinoma (XF 354) had a faster growth rate and a more characteristic histology than did the cell line from the primary tumor of a squamous cell carcinoma of the floor of the mouth (UM-SCC-14C).
  • The combination of the XF 354 tumor cell line and the RAG 2 mouse was most successful, with a tumor growth rate of 95%.
  • Our animal model is very reliable and allows manipulations for as long as 30 min under anesthesia outside of microbiologic safety cabinets, where the handling of animals is much more comfortable and less time-consuming.
  • Steps for cell cultivation and tumor implantation are described and discussed.
  • Therefore we strongly recommend the use of the model comprising the RAG 2 mouse with the xenografted cell line XF 354 for research in the field of human oral squamous cell carcinoma.


20. Lo WL, Kao SY, Chi LY, Wong YK, Chang RC: Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. J Oral Maxillofac Surg; 2003 Jul;61(7):751-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival.
  • PURPOSE: The study goal was to determine which clinical features correlated with 5-year survival in patients surgically treated for oral squamous cell carcinoma (OSCC) in Taiwan.
  • PATIENTS AND METHODS: The records of 378 OSCC patients surgically treated with or without chemotherapy and radiotherapy were reviewed retrospectively.
  • Neck nodal metastasis occurred frequently at the floor of the mouth (in >60% of cases), followed by the gingiva (45.7%), buccal mucosa (34%), and tongue (20.4%), whereas early distant metastasis was rare (5.3%).
  • CONCLUSIONS: Our data suggest that early treatment is the key to increasing the survival of OSCC patients.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Mouth Neoplasms / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Alcohol Drinking / adverse effects. Areca / adverse effects. Chemotherapy, Adjuvant. Female. Humans. Linear Models. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Sex Factors. Smoking / adverse effects. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12856245.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Wolf JS, Li D, Taylor RJ, O'Malley BW Jr: Lactoferrin inhibits growth of malignant tumors of the head and neck. ORL J Otorhinolaryngol Relat Spec; 2003 Sep-Oct;65(5):245-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using an orthotopic murine model for both squamous cell carcinoma and fibrosarcoma of the floor of the mouth, we administered lactoferrin directly into the tumors using variable dosing strategies.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Fibrosarcoma / drug therapy. Head and Neck Neoplasms / drug therapy. Lactoferrin / therapeutic use
  • [MeSH-minor] Animals. Cell Line. Disease Models, Animal. Dose-Response Relationship, Drug. Humans. Immunocompetence. Injections, Intralesional. Mice. Mice, Inbred C3H. Mice, Nude. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14730178.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 3.4.21.- / Lactoferrin
  •  go-up   go-down


22. Yang H, Liu S, Liang C, Peng W: [Studies of mouse interleukin-2 gene therapy for head, and neck sequamous cell carcinoma using polycationic liposome-mediated transduction]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan;34(1):9-11, 30
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Studies of mouse interleukin-2 gene therapy for head, and neck sequamous cell carcinoma using polycationic liposome-mediated transduction].
  • OBJECTIVE: To investigate the immunological mechanism of mouse IL-2 gene therapy and the optimal lipid to DNA ratios of lipid-DNA complexed (lipoplexes) by using polycationic liposome-mediated Tumors were established in the transduction for head and neck squamous cell carcinoma (HNSCC).
  • METHODS: floor of mouth in C3H/HeJ immunocompetent mice with SCCVII cell line.
  • The supernatants of SCCVII cell and tumour tissues were collected for IL-2 expression by enzyme-linked immunosorbent assay.
  • Natural killer (NK) cell activity and cytotoxic T-lymphocyte (CTL) activity were also The optimal L:D ratio for IL-2 expression in vitro was not assayed by lactate dehydrogenase method.
  • By use of lipoplexes with L:D = 3:1, higher IL-2 expression of tumor tissues and greater activities of NK cell and CTL of murine spleen were noted in the treated group as compared with those A comparison of naked plasmid and lipid-complexed found in naked DNA and empty plasmid (EP).
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Genetic Therapy. Head and Neck Neoplasms / therapy. Interleukin-2 / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Drug Carriers. Killer Cells, Natural / immunology. Lipids. Mice. Mice, Inbred C3H. Neoplasm Transplantation. Polyamines. T-Lymphocytes, Cytotoxic / drug effects. Transfection / methods

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15600166.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Interleukin-2; 0 / Lipids; 0 / Lipofectamine; 0 / Polyamines; 0 / polycations
  •  go-up   go-down


23. Mallia RJ, Subhash N, Sebastian P, Kumar R, Thomas SS, Mathews A, Madhavan J: In vivo temporal evolution of ALA-induced normalized fluorescence at different anatomical locations of oral cavity: application to improve cancer diagnostic contrast and potential. Photodiagnosis Photodyn Ther; 2010 Sep;7(3):162-75
MedlinePlus Health Information. consumer health - Mouth Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo temporal evolution of ALA-induced normalized fluorescence at different anatomical locations of oral cavity: application to improve cancer diagnostic contrast and potential.
  • BACKGROUND: The focal goal of this study is to identify optimal accumulation periods for ALA-induced PpIX in different healthy anatomical sites of human oral cavity and different types of abnormal mucosa to improve the accuracy of the clinical applications such as photodiagnosis and tissue grading.
  • The optimal accumulation time in different anatomical sites of healthy subjects and abnormal tissues were determined by studying the temporal variation in normalized fluorescence intensities (NFI) at 635, 685 and 705 nm.
  • RESULTS AND DISCUSSIONS: In masticatory anatomical locations such as (gingival and hard palate) and in lining mucosa (inner lip, soft palate, floor of mouth, transition to floor of mouth, alveolus and ventral tongue) except vermillion border of lip (VBL) of healthy subjects (designated as group I), it was observed that optimum time for maximum accumulation of PpIX is 90 min.
  • In comparison, for lateral side of tongue (LST) and dorsal side of tongue (DST) tissues (designated as group II), maximum accumulation of PpIX was observed in 150 min of ALA application.
  • For diverse grade lesions of group I mucosa in patients, maximum accumulation of PpIX was observed in 90 min, whereas, in group II mucosa the optimum accumulation time was 150 min as in the case of healthy mucosa.
  • Further, between different grades oral mucosa, maximum variation in NFI take place at these optimal time periods.
  • CONCLUSIONS: The determination of the optimum accumulation time of ALA in oral mucosa based on NFI helps to improve the diagnostic contrast and accuracy of oral cancer diagnosis, and to plan appropriate timing for ensuing PDT.
  • [MeSH-major] Aminolevulinic Acid / pharmacokinetics. Mouth / metabolism. Mouth Diseases / diagnosis. Mouth Mucosa / anatomy & histology. Protoporphyrins / metabolism
  • [MeSH-minor] Administration, Topical. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Diagnosis, Oral. Humans. Mouth Neoplasms / diagnosis. Mouth Neoplasms / drug therapy. Mouth Neoplasms / pathology. Photochemotherapy. Spectrometry, Fluorescence. Time Factors

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20728840.001).
  • [ISSN] 1873-1597
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


24. Gomez DR, Zhung JE, Gomez J, Chan K, Wu AJ, Wolden SL, Pfister DG, Shaha A, Shah JP, Kraus DH, Wong RJ, Lee NY: Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers. Int J Radiat Oncol Biol Phys; 2009 Mar 15;73(4):1096-103
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers.
  • PURPOSE: To present our single-institution experience of intensity-modulated radiotherapy (IMRT) for oral cavity cancer.
  • METHODS AND MATERIALS: Between September 2000 and December 2006, 35 patients with histologically confirmed squamous cell carcinoma of the oral cavity underwent surgery followed by postoperative IMRT.
  • The sites included were buccal mucosa in 8, oral tongue in 11, floor of the mouth in 9, gingiva in 4, hard palate in 2, and retromolar trigone in 1.
  • Ten patients (29%) also received concurrent postoperative chemotherapy with IMRT.
  • The median prescribed radiation dose was 60 Gy.
  • Treatment failure occurred in 11 cases as follows: local in 4, regional in 2, and distant metastases in 5.
  • CONCLUSION: IMRT as an adjuvant treatment after surgical resection for oral cavity tumors is feasible and effective, with promising results and acceptable toxicity.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Male. Middle Aged. Radiation Injuries / etiology. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707827.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


25. Petruzzi M, De Benedittis M, Pastore L, Pannone G, Grassi FR, Serpico R: Isolated lichen planus of the lip. Int J Immunopathol Pharmacol; 2007 Jul-Sep;20(3):631-5
Hazardous Substances Data Bank. Clobetasol .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oral lichen planus (OLP) is a relatively common disorder whose cause is still unknown.
  • It occurs mostly on the buccal mucosa, but the gingivae, tongue, floor of the mouth and retromalar pads may also be affected.
  • A complete remission of lesions was observed in eight patients after topical treatment with clobetasol propionate 0.05 percent and tocopherol oil, while partial improvement was noted in those remaining.
  • Isolated LP of the lip is unusual and presents a diagnostic challenge; however an appropriate differential diagnosis is fundamental.
  • Isolated LP of the lip is a well-known condition which responds well to topical treatment with corticosteroids.
  • A thorough medical management and active early treatment are necessary to improve symptoms and might also be a relevant prevention strategy from squamous cell carcinoma risk, although data to fully support this statement still need investigation.
  • [MeSH-major] Lichen Planus, Oral / drug therapy. Lip / drug effects
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Anti-Inflammatory Agents / administration & dosage. Anti-Inflammatory Agents / therapeutic use. Clobetasol / administration & dosage. Clobetasol / therapeutic use. Cohort Studies. Drug Combinations. Female. Humans. Male. Middle Aged. Tocopherols / administration & dosage. Tocopherols / therapeutic use. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17880776.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Drug Combinations; 1406-66-2 / Tocopherols; ADN79D536H / Clobetasol
  •  go-up   go-down


26. Paulino AF, Singh B, Shah JP, Huvos AG: Basaloid squamous cell carcinoma of the head and neck. Laryngoscope; 2000 Sep;110(9):1479-82
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma of the head and neck.
  • OBJECTIVE/HYPOTHESIS: Basaloid squamous cell carcinoma (BSCC), an uncommon tumor with predilection for the upper aerodigestive tract, is a distinct variant of squamous carcinoma, because of its unique histological features and ominous clinical behavior.
  • Sites of origin included the larynx (4), tongue (3), pyriform sinus (3), nose (2), floor of mouth (2), mastoid (1), tonsil (1), epiglottis (1), nasopharynx (1), trachea (1), and palate (1).
  • Treatment modalities included surgery with or without chemotherapy or radiotherapy in 13 patients, chemotherapy with irradiation in 2, chemotherapy alone in 2, and radiotherapy alone in 3.
  • Four were alive with disease at the time of writing and five died of disease.
  • Greater number of patients must be studied and compared with age-matched and stage-matched controls of conventional squamous cell carcinoma to determine whether the poor clinical outcome is related more to high-stage presentation or to the tumor's high-grade malignant cytological features.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10983946.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


27. Inagi K, Takahashi H, Okamoto M, Nakayama M, Makoshi T, Nagai H: Treatment effects in patients with squamous cell carcinoma of the oral cavity. Acta Otolaryngol Suppl; 2002;(547):25-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment effects in patients with squamous cell carcinoma of the oral cavity.
  • A total of 221 patients (155 males, 66 females; stage I, n = 55: stage II, n = 58; stage III, n = 57; stage IV, n = 51) with squamous cell carcinoma of the oral cavity were studied.
  • Tumor localization was as follows: cancer of the tongue, n = 161; cancer of the oral floor, n = 28; cancer of the hard palate, n = 12; cancer of the buccal mucosa, n = 11; and cancer of the gingiva, n = 9.
  • In order to compare the effect of different treatments, three major treatment groups were defined, namely a surgery group, a radiotherapy group and a combination treatment group.
  • The 5-year cumulative survival rate was highest for oral floor cancer (80%).
  • In the early-cancer group, the 5-year cumulative survival rate for the surgery group (92%) was significantly higher (p < 0.05) than those for both the radiation (69%) and combination (71%) groups.
  • In the advanced-cancer group, the 5-year cumulative survival rate for the surgery group (74%) was significantly higher (p < 0.05) than those for both the radiation (37%) and combination (51%) groups.
  • No significant difference in regional control rates was observed between the treatment groups.
  • [MeSH-major] Antineoplastic Protocols. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Mouth / drug effects. Mouth / radiation effects. Mouth Neoplasms / mortality. Mouth Neoplasms / therapy. Outcome Assessment (Health Care)
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Severity of Illness Index. Survival Rate


28. Kübler AC, Reuther T, Staff C, Haase T, Flechtenmacher C, Benner A, Scheer M, Zillmann U: [Clinical effectiveness of m-THPC-PEG in a new xenogenic animal tumor model for human squamous epithelial carcinomas]. Mund Kiefer Gesichtschir; 2001 Mar;5(2):105-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical effectiveness of m-THPC-PEG in a new xenogenic animal tumor model for human squamous epithelial carcinomas].
  • BACKGROUND: Animal tumor models are still essential for the development of new medication and therapy concepts.
  • For the field of oropharyngeal cancer only few reliable xenogeneic tumor models are available.
  • PART 1 OF THE STUDY: The growth rates of two different tumor cell lines were compared in the RAG-2 mouse, the SCID mouse and the Swiss nude mouse.
  • Cells from a lymph-node metastasis of an oral squamous cell carcinoma (XF-354) showed a better growth rate and clearer histology than cells from a primary squamous cell carcinoma of the floor of the mouth (UM-SCC-14C).
  • The combination of the XF-354 tumor cell line and the RAG-2 mouse was the most successful, with a tumor growth rate of 95%.
  • The single steps for cell cultivation and tumor implantation are described and discussed in detail.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Survival / drug effects. Disease Models, Animal. Mesoporphyrins / pharmacology. Oropharyngeal Neoplasms / pathology. Photochemotherapy. Polyethylene Glycols / pharmacology. Tumor Cells, Cultured / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11372175.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / temoporfin-polyethylene glycol conjugate; 30IQX730WE / Polyethylene Glycols
  •  go-up   go-down


29. Couch M, Saunders JK, O'Malley BW Jr, Pardoll D, Jaffee E: Genetically engineered tumor cell vaccine in a head and neck cancer model. Laryngoscope; 2003 Mar;113(3):552-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetically engineered tumor cell vaccine in a head and neck cancer model.
  • OBJECTIVES: Using a murine model, a novel tumor vaccine for head and neck squamous cell carcinoma expressing the granulocyte-macrophage colony stimulating factor (GM-CSF) gene was evaluated for its ability to protect against tumor challenge.
  • STUDY DESIGN: Mice vaccinated in the floor of the mouth with the GM-CSF tumor cell vaccine were challenged with parental tumor cells, and subsequent tumor development was monitored.
  • Specificity of the antitumor response was demonstrated by vaccinating the mice and then challenging them with an unrelated but syngeneic radiation-induced fibrosarcoma tumor cell line, RIF.
  • GM-CSF concentrations were determined using ELISA, and physiological activity was confirmed using a biological assay with a GM-CSF-dependent cell line.
  • Mice were not protected when vaccinated and challenged with the unrelated tumor cell line, RIF.
  • This work supports the continued investigation of the GM-CSF tumor vaccine for the treatment of head and neck squamous cell carcinoma.
  • [MeSH-major] Cancer Vaccines / genetics. Cancer Vaccines / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Genetic Engineering / methods. Head and Neck Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12616213.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


30. Buch RS, Geisbüsch R, Kunkel M: [Acral ischemia as a rare paraneoplastic syndrome in the terminal phase of mouth floor carcinoma]. Mund Kiefer Gesichtschir; 2002 Sep;6(5):331-5
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acral ischemia as a rare paraneoplastic syndrome in the terminal phase of mouth floor carcinoma].
  • Symptoms evolved under palliative chemotherapy with gemcitabine for inoperable metachronous squamous cell carcinoma of the tonsil following a history of two simultaneous carcinomas of the alveolar crest.
  • Digital ischemia was combined with severe pain, similar to Raynaud's syndrome, which required therapeutic intervention.
  • The treatment objective is to improve perfusion and simultaneously reduce pain.
  • [MeSH-major] Alveolar Process. Carcinoma, Squamous Cell / diagnosis. Fingers / blood supply. Ischemia / etiology. Maxillary Neoplasms / diagnosis. Mouth Floor. Mouth Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Palliative Care. Paraneoplastic Syndromes / etiology. Tonsillar Neoplasms / diagnosis
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male. Necrosis. Raynaud Disease / therapy. Sympathectomy. Vasodilator Agents / administration & dosage

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12448236.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Vasodilator Agents
  •  go-up   go-down


31. Okutomi T, Kato Y, Ichihara H, Hyodo I, Fujitsuka H, Yasuda S, Tatematsu N: [Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer--prevention of stomatitis and hematopoietic impairment]. Gan To Kagaku Ryoho; 2000 Jan;27(1):65-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer--prevention of stomatitis and hematopoietic impairment].
  • A combination of radiotherapy and chemotherapy is a usual treatment method for malignant head and neck tumors, however chemoradiotherapy is associated with hematopoietic impairment and serious stomatitis in patients.
  • The clinical effects and evaluation of hematopoietic activity (e.g., leukocyte count) and the degree of stomatitis under adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer were investigated for preoperative cancer therapy.
  • In order to evaluate the clinical effects of Ancer 20 injection with regard to hematopoietic activity and the degree of stomatitis, a clinical study was performed for 18 patients with oral cancer in our department.
  • The 18 patients, who had oral squamous cell carcinomas (5 of the tongue, 4 of the mandibular gingiva, 3 of the maxillary gingiva, 1 of the floor of the mouth, 3 of the buccal mucosa, and 2 others), were treated with this combination of adjuvant therapy with Ancer 20 injection, from March, 1991 to March, 1997.
  • They were injected with Ancer 20 (twice a week, 40 micrograms) during the cancer treatment period.
  • We investigated hematopoietic activity, (e.g., leukocyte and platelet counts) and the degree of stomatitis periodically, before and after the combined radiotherapy and chemotherapy treatment period.
  • These results suggest that Ancer 20 injection may generally improve various dysfunctions due to hematopoietic impairment by radiotherapy combined with chemotherapy, and improve immunological factors.
  • We conclude that Ancer 20 injection is a useful adjuvant treatment for oral cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Leukopenia / prevention & control. Mouth Neoplasms / drug therapy. Radiation-Protective Agents / administration & dosage. Stomatitis / prevention & control
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Leukocyte Count. Lipids / administration & dosage. Mannans / administration & dosage. Radiotherapy Dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10660735.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Lipids; 0 / Mannans; 0 / Radiation-Protective Agents; 0 / specific substance maruyama
  •  go-up   go-down


32. Lin CY, Wang HM, Kang CJ, Lee LY, Huang SF, Fan KH, Chen EY, Chen IH, Liao CT, Chang JT: Primary tumor site as a predictor of treatment outcome for definitive radiotherapy of advanced-stage oral cavity cancers. Int J Radiat Oncol Biol Phys; 2010 Nov 15;78(4):1011-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary tumor site as a predictor of treatment outcome for definitive radiotherapy of advanced-stage oral cavity cancers.
  • PURPOSE: To evaluate the outcome of definitive radiotherapy (RT) for oral cavity cancers and to assess prognostic factors.
  • METHODS AND MATERIALS: Definitive RT was performed on 115 patients with oral cavity cancers at Stages III, IVA, and IVB, with a distribution of 6%, 47%, and 47%, respectively.
  • The median dose of RT was 72 Gy (range, 62-76 Gy).
  • Cisplatin-based chemotherapy was administered to 95% of the patients.
  • RESULTS: Eight-eight (76.5%) patients responded partially and 23 (20%) completely; of the patients who responded, 18% and 57%, respectively, experienced a durable effect of treatment.
  • The 3-year PFS rates based on the primary tumor sites were as follows: Group I (buccal, mouth floor, and gum) 51%, Group II (retromolar and hard palate) 18%, and Group III (tongue and lip) 6% (p < 0.0001).
  • The T stage and RT technique did not affect survival.
  • CONCLUSION: The primary tumor site and neck stage are prognostic predictors in advanced-stage oral cancer patients who received radical RT.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Cause of Death. Cisplatin / therapeutic use. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Radiation Injuries / pathology. Salvage Therapy / mortality. Survival Analysis. Taiwan. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20434273.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


33. Adappa ND, Sung CK, Choi B, Huang TG, Genden EM, Shin EJ: The administration of IL-12/GM-CSF and Ig-4-1BB ligand markedly decreases murine floor of mouth squamous cell cancer. Otolaryngol Head Neck Surg; 2008 Sep;139(3):442-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The administration of IL-12/GM-CSF and Ig-4-1BB ligand markedly decreases murine floor of mouth squamous cell cancer.
  • OBJECTIVE: To assess immune-based gene therapy in a murine floor of mouth (FOM) squamous cell carcinoma (SCC) model.
  • STUDY DESIGN: In vitro and in vivo testing of immune therapy for SCC.
  • METHODS: Multiple SCC lines were infected by using advRSV-interleukin-12 (IL-12) and advCMV-interleukin-12/granulocyte macrophage colony-stimulating factor (IL-12/GM-CSF) and monitored for production of IL-12 and GM-CSF.
  • Intratumoral injections of viral vectors were administered with systemic Ig-4-1BB ligand in an orthotopic murine FOM SCC model and followed for tumor size and survival.
  • RESULTS: In vitro, all cell lines produced substantial levels of IL-12 and GM-CSF.
  • CONCLUSION: Combination immune-based therapies effectively improve survival in mice bearing FOM SCC over single-modality therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Genetic Therapy / methods. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Interleukin-12 / administration & dosage. Mouth Neoplasms / therapy
  • [MeSH-minor] Animals. Drug Synergism. Enzyme-Linked Immunosorbent Assay. Immunotherapy / methods. Mice. Mouth Floor. Time Factors. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18722228.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 187348-17-0 / Interleukin-12; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


34. Harada K, Sato M, Ueyama Y, Nagayama M, Hamakawa H, Nagahata S, Yoshimura Y, Osaki T, Ryoke K, Oral Cancer Study Group of Chugoku-Shikoku: Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma. Anticancer Drugs; 2008 Jan;19(1):85-90
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma.
  • The aim of this study was to investigate the efficacy and safety of an oral fluoropyrimidine anticancer agent, S-1, in patients with oral squamous cell carcinoma.
  • Patients with pathologically confirmed squamous cell carcinoma and at least one measurable lesion were enrolled.
  • The sites of the primary tumor were the gingiva (n=18), the tongue (n=12), the palate (n=5), the oral floor (n=4), the buccal mucosa (n=1), and the labial mucosa (n=1).
  • A median of two cycles of treatment (range, 1-5) was administered.
  • S-1 exhibits definite antitumor activity in patients with oral squamous cell carcinoma and is well tolerated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Drug Combinations. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043133.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


35. O'Malley BW Jr, Li D, McQuone SJ, Ralston R: Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. Laryngoscope; 2005 Mar;115(3):391-404
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
  • OBJECTIVE/HYPOTHESIS: Intralesional delivery of cytokine genes has emerged as a promising therapeutic strategy for the treatment of cancer.
  • In addition to the therapeutic effect of the delivered cytokine gene, the components of the gene delivery system also have been shown to induce beneficial immune responses.
  • On the basis of these principles, we hypothesized that a molecular therapy could be developed that would provide synergistic antitumor activity by way of intralesional expression of interleukin (IL)-2 from a recombinant plasmid combined with induction of endogenous interferon (IFN)-gamma and IL-12 cytokines by immunostimulatory DNA.
  • STUDY DESIGN: Prospective laboratory drug development plan that would produce human clinical trials.
  • MATERIALS AND METHODS: Engineered bacterial plasmids containing a cytomegalovirus promoter (CMV)-IL-2 expression cassette were specifically formulated with cationic lipids and optimized for antitumor effect in a floor of mouth murine tumor model.
  • Immunologic studies were performed and included cytolytic T-cell assays and cytokine expression profiles.
  • For human clinical trials, a phase I 10 patient formulated IL-2 gene therapy study was completed.
  • Subsequently, two large scale, phase II multi-institutional and multi-international studies were initiated comparing non-viral IL-2 gene therapy to palliative methotrexate chemotherapy or in combination with cisplatin.
  • Consistent with previously reported studies of the immunostimulatory activity of DNA of bacterial origin, treatment of tumors with control plasmid in cationic lipid formulation induced production of endogenous IFN-gamma and IL-12 but not IL-2.
  • Treatment of tumors with formulated IL-2 plasmid produced IL-2 protein levels that were 5-fold over background and increased IFN-gamma by 32-fold (P < .001) and IL-12 by 5.5-fold (P < .001) compared with control plasmid formulations.
  • The phase II studies have been initiated and focus on either comparing the novel nonviral IL-2 gene immunotherapy formulation alone to methotrexate or comparing IL-2 gene therapy in combination with cisplatin in recurrent or unresectable patients with head and neck squamous cell carcinoma.
  • CONCLUSIONS: The preclinical data provided proof of principle for matching a delivered IL-2 transgene with an immunostimulatory nonviral formulation to enhance intralesional production of therapeutic cytokines for the maximization of antitumor response.
  • Human clinical trials have demonstrated this novel therapy to be safe in the human clinical setting.
  • Phase II trials have been initiated to assess efficacy and feasibility as a single or combination therapy for head and neck cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Genetic Therapy / methods. Head and Neck Neoplasms / therapy. Immunotherapy / methods. Interleukin-2 / therapeutic use
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Dose-Response Relationship, Drug. Double-Blind Method. Humans. Immunosuppressive Agents / therapeutic use. Interferon-gamma / metabolism. Interleukin-12 / metabolism. Methotrexate / therapeutic use. Mice. Mice, Inbred C3H. Palliative Care. Plasmids. Polymerase Chain Reaction. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Transgenes

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744147.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 0 / Interleukin-2; 0 / RNA, Messenger; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


36. Fuwa N, Kodaira T, Furutani K, Tachibana H, Nakamura T: A new method of selective intra-arterial infusion therapy via the superficial temporal artery for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Jun;105(6):783-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new method of selective intra-arterial infusion therapy via the superficial temporal artery for head and neck cancer.
  • STUDY DESIGN: This study included 92 patients who were treated by this combination therapy between May 1999 and December 2004.
  • Primary tumor sites included the tongue in 73 patients, base of the tongue in 6 patients, floor of mouth in 4 patients, buccal mucosa in 4 patients, and other sites in 5 patients.
  • In 4 patients, the catheter fell out of the selected artery during treatment.
  • CONCLUSION: This selective intra-arterial method will be an important modality for advanced tongue cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carboplatin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Radiography, Interventional / methods. Tongue Neoplasms / drug therapy

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206406.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


37. Rohde S, Turowski B, Berkefeld J, Kovács AF: [Clinical and histopathological results after local chemoembolization of oral and oropharyngeal carcinoma--comparison with intraarterial chemoperfusion]. Rofo; 2006 Oct;178(10):979-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and histopathological results after local chemoembolization of oral and oropharyngeal carcinoma--comparison with intraarterial chemoperfusion].
  • [Transliterated title] Klinische und histopathologische Ergebnisse nach lokaler Chemoembolisation oraler und oropharyngealer Karzinome--Vergleich mit intraarterieller Chemoperfusion.
  • PURPOSE: Retrospective analysis of clinical and histopathological results after neoadjuvant intraarterial chemoembolization (iaCE) as compared to intraarterial chemoperfusion (iaCP) in patients with oral and oropharyngeal squamous cell cancer (SCC).
  • MATERIALS AND METHODS: 289 patients (mean age 60 years, 68 % male) with SCC of the oral cavity or the oropharynx (WHO stage I-IV) received (1) neoadjuvant iaCE (n = 103) with a crystalline suspension of cisplatin (150 mg/m(2), solution ratio 5 mg cisplatin ad 1 ml NaCl 0.9 %, total volume 40 - 60 ml) or (2) iaCP (n = 186) using high-dose cisplatin infusions (150 mg/m(2), 1 mg cisplatin ad 1 ml NaCl 0.9 %, 400 - 500 ml).
  • The decision for iaCE or iaCP was made individually for each patient based on tumor localization and expected vascular supply.
  • Four weeks after local chemotherapy, the treatment response was evaluated according (1) to WHO criteria and (2) to histopathological TNM-grading after tumor resection.
  • RESULTS: The overall treatment response was 72.5 % after iaCE and 47 % after iaCP (p < 0.001).
  • Local side effects were significantly more frequent after iaCE than after iaCP (p < 0.001), especially in obese patients with extended carcinoma of the oral floor or the tongue base.
  • However, in view of the higher risk of regional complications, indication for iaCE should be considered cautiously and its application should be limited to small tumors of the oral floor and the oral tongue.
  • [MeSH-major] Chemoembolization, Therapeutic / methods. Cisplatin / administration & dosage. Mouth Neoplasms / pathology. Mouth Neoplasms / therapy. Oropharyngeal Neoplasms / pathology. Oropharyngeal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Female. Germany / epidemiology. Humans. Injections, Intra-Arterial. Male. Middle Aged. Outcome Assessment (Health Care). Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rofo. 2006 Dec;178(12):1266. Kovács, A [corrected to Kovács, A F]
  • (PMID = 17021977.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


38. Li D, Shugert E, Guo M, Bishop JS, O'Malley BW Jr: Combination nonviral interleukin 2 and interleukin 12 gene therapy for head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg; 2001 Nov;127(11):1319-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination nonviral interleukin 2 and interleukin 12 gene therapy for head and neck squamous cell carcinoma.
  • OBJECTIVE: To determine the feasibility and efficacy of combination nonviral lipid-formulated murine interleukin 2 (mIL-2) and polymer-formulated murine interleukin 12 (mIL-12) gene therapy for head and neck squamous cell carcinoma (HNSCC) in a murine model.
  • Tumors were established in the floor of mouth in C3H/HeJ immunocompetent mice.
  • Antitumor responses, cytokine expression, and natural killer cell and cytolytic T-lymphocyte activity were assayed.
  • RESULTS: The use of combined mIL-2 and mIL-12 gene therapy resulted in significant antitumor effects, compared with each of the single-cytokine and no-treatment (control) groups (P =.01 to P =.02).
  • Combined mIL-2 and mIL-12 treatment consistently produced the greater activation of cytolytic T-lymphocyte and natural killer cells than did single-cytokine treatment or other controls at all concentrations tested.
  • Combined nonviral IL-2 and IL-12 gene therapy may have great potential as a primary or adjuvant treatment for HNSCC in humans.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Genetic Therapy / methods. Head and Neck Neoplasms / drug therapy. Interleukin-12 / genetics. Interleukin-2 / genetics
  • [MeSH-minor] Adjuvants, Immunologic / genetics. Adjuvants, Immunologic / therapeutic use. Animals. Antineoplastic Agents / immunology. Antineoplastic Agents / therapeutic use. Disease Models, Animal. Drug Therapy, Combination. Gene Transfer Techniques. Injections, Intralesional. Killer Cells, Natural / immunology. Mice. Plasmids. Statistics, Nonparametric. T-Lymphocytes, Cytotoxic / immunology

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11701067.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents; 0 / Interleukin-2; 187348-17-0 / Interleukin-12
  •  go-up   go-down


39. Ikeda H, Kitamura A, Uehara M, Tobita T, Ohba S, Nonaka M, Fujisawa A, Inokuchi T: [A case of squamous cell carcinoma of the oral floor showing a complete response to oral administration of UFT]. Gan To Kagaku Ryoho; 2001 Nov;28(12):1929-31
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of squamous cell carcinoma of the oral floor showing a complete response to oral administration of UFT].
  • A 73-year-old male with squamous cell carcinoma of the oral floor (T1N0M0), who had not consented to radical treatment was treated with UFT by oral administration alone.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Tegafur / therapeutic use. Uracil / therapeutic use
  • [MeSH-minor] Administration, Oral. Aged. Drug Combinations. Humans. Male. Remission Induction

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11729490.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil
  •  go-up   go-down


40. Maurizio SJ, Eckart AL: A case study associated with oropharyngeal cancer. J Dent Hyg; 2010;84(4):170-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case study associated with oropharyngeal cancer.
  • PURPOSE: Squamous cell carcinoma (SCC) is the most common oral malignancy, commonly located on the anterior floor of the mouth, lateral borders of the tongue, tonsillar pillars and lateral soft palate.
  • A 59 year old male presented to a Midwestern university dental hygiene clinic following referral for pre-radiation and chemotherapy oral prophylaxis and comprehensive examination.
  • Biopsy confirmed the diagnosis of SCC of the left tonsil.
  • Surgery, radiation and chemotherapy were performed.
  • Dental hygienists should document significant findings and notify the dentist of abnormalities and the need for subsequent referral, providing early detection results in improved prognosis for those who encounter experiences with oral, head and neck cancer.

  • MedlinePlus Health Information. consumer health - Tooth Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21047462.001).
  • [ISSN] 1553-0205
  • [Journal-full-title] Journal of dental hygiene : JDH
  • [ISO-abbreviation] J Dent Hyg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Turowski B, Zanella FE: Interventional neuroradiology of the head and neck. Neuroimaging Clin N Am; 2003 Aug;13(3):619-45
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vascular interventions are important and helpful for treatment of various pathologies of the head and neck.
  • Interventional neuroradiology of the head and neck includes image-guided biopsies, vessel occlusion, and local chemotherapy.
  • Knowledge of anatomy, functional relationships between intra- and extracranial vessels, and pathology are the basis for therapeutic success.
  • Neuroradiologic imaging, especially CT and MR imaging, and appropriate analysis of angiographic findings help ensure indication for treatment and plan an intervention.
  • Effective treatment of vascular malformations, such as AV fistulas or angiomas, needs exact occlusion of the fistula or the angiomatous nidus, which is demonstrated in the case of an AV angioma of the base of the tongue.
  • Chemotherapy with local intra-arterial cisplatin combined with intravenous administration of sodium thiosulfate as antidote is indicated as an adjuvant modality in a multimodal regimen of oropharyngeal squamous cell carcinoma or as palliative treatment of recurrent and otherwise untreatable malignant tumors of the head and neck.
  • Examples are a carcinoma of the alveolar ridge, a squamous cell carcinoma of the floor of the mouth, and a nasopharyngeal lymphoepithelioma.
  • Palliative treatment of a bleeding oropharyngeal cancer is another example of interventional treatment.
  • Selective treatment, either occluding or pharmacologic, may be preoperative, palliative, or curative.
  • The objective is reduction of surgical risk, improvement of quality of life, or curative therapy of a lesion.
  • Thus, the interventional treatment should not be associated with morbidity or mortality.
  • The benefits, risks, and expected damages of neuroradiologic interventions must be balanced during the informed consent procedure with the patient.
  • [MeSH-major] Head and Neck Neoplasms / radiography. Head and Neck Neoplasms / therapy. Neuroradiography. Radiology, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14631695.001).
  • [ISSN] 1052-5149
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


42. Budach W: [Intra-arterial preoperative chemotherapy versus preoperative radiotherapy]. Strahlenther Onkol; 2001 Feb;177(2):113-4
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intra-arterial preoperative chemotherapy versus preoperative radiotherapy].
  • [Transliterated title] Intraarterielle präoperative Chemotherapie versus präoperative Strahlentherapie.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Infusions, Intra-Arterial. Mouth Floor. Mouth Neoplasms / drug therapy. Mouth Neoplasms / radiotherapy. Tongue Neoplasms / drug therapy. Tongue Neoplasms / radiotherapy
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Carotid Artery, External. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Epirubicin / administration & dosage. Follow-Up Studies. Humans. Neoplasm Recurrence, Local / prevention & control. Odds Ratio. Osteoradionecrosis / etiology. Preoperative Care. Quality of Life. Radiotherapy / adverse effects. Radiotherapy Dosage. Radiotherapy, Adjuvant. Surveys and Questionnaires. Time Factors

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11233834.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] ger
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement